| Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial K Reich, K Kabashima, K Peris, JI Silverberg, LF Eichenfield, T Bieber, ... JAMA dermatology 156 (12), 1333-1343, 2020 | 253 | 2020 |
| Efficacy and safety of ixekizumab in a randomized, double‐blinded, placebo‐controlled phase IIIb study of patients with moderate‐to‐severe genital psoriasis C Ryan, A Menter, L Guenther, A Blauvelt, R Bissonnette, K Meeuwis, ... British journal of dermatology 179 (4), 844-852, 2018 | 113 | 2018 |
| Effect of ixekizumab treatment on work productivity for patients with moderate-to-severe plaque psoriasis: analysis of results from 3 randomized phase 3 clinical trials AW Armstrong, CW Lynde, SR McBride, M Ståhle, E Edson-Heredia, ... JAMA dermatology 152 (6), 661-669, 2016 | 51 | 2016 |
| Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate‐to‐severe atopic dermatitis with inadequate response, intolerance or … T Bieber, K Reich, C Paul, Y Tsunemi, M Augustin, JP Lacour, ... British Journal of Dermatology 187 (3), 338-352, 2022 | 48 | 2022 |
| Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate‐to‐severe atopic … A Wollenberg, T Nakahara, C Maari, K Peris, P Lio, M Augustin, ... Journal of the European Academy of Dermatology and Venereology 35 (7), 1543-1552, 2021 | 48 | 2021 |
| Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials B King, A Mostaghimi, Y Shimomura, A Zlotogorski, GS Choi, ... British Journal of Dermatology 188 (2), 218-227, 2023 | 30 | 2023 |
| Efficacy and safety of baricitinib in combination with topical corticosteroids in moderate to severe atopic dermatitis: results of a phase 3 randomized, double-blind, placebo … K Reich, K Kabashima, K Peris, J Kolodsick, FE Yang, M Gamalo Abstract presented at: European Academy of Dermatology and Venereology 28th …, 2019 | 24 | 2019 |
| Early onset of clinical improvement with ixekizumab in a randomized, open-label study of patients with moderate-to-severe plaque psoriasis S Khattri, O Goldblum, K Solotkin, Y Amir, MS Min, T Ridenour, FE Yang, ... The Journal of Clinical and Aesthetic Dermatology 11 (5), 33, 2018 | 18 | 2018 |
| Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled, phase 3b clinical trial in patients with moderate-to-severe genital psoriasis C Ryan, A Menter, L Guenther, A Blauvelt, R Bissonnette, FE Yang, ... SKIN The Journal of Cutaneous Medicine 2, S8-S8, 2018 | 13 | 2018 |
| Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis E Guttman-Yassky, S Weidinger, E Simpson, M Gooderham, A Irvine, ... SKIN The Journal of Cutaneous Medicine 7 (6), s271-s271, 2023 | 5 | 2023 |
| Safety analysis of baricitinib in adult patients with severe alopecia areata from 2 randomized clinical trials over a median of 1.6 years and up to 3.6 years of exposure B King, J Ko, BM Piraccini, Y Shimomura, Y Dutronc, WS Wu, FE Yang, ... American Academy of Dermatology 81st annual meeting, 0 | 2 | |
| EFFICACY AND SAFETY OF BARICITINIB IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN MODERATE-TO-SEVERE ATOPIC DERMATITIS PATIENTS WITH CYCLOSPORINE FAILURE, INTOLERANCE, OR … T Bieber, K Reich, C Paul, Y Tsunemi, M Augustin, JP Lacour, ... ACTA DERMATO-VENEREOLOGICA 101, 63-63, 2021 | 1 | 2021 |
| 012 Efficacy and Safety of Ixekizumab in a Randomized, Double-Blinded, Placebo-Controlled, Phase 3b Clinical Trial in Patients with Moderate-to-Severe Genital Psoriasis C Ryan, A Menter, L Guenther, A Blauvelt, R Bissonnette, FE Yang, ... The Journal of Sexual Medicine 15 (Supplement_1), S6-S7, 2018 | 1 | 2018 |
| Early onset of clinical improvement with ixekizumab in patients with moderate-to-severe plaque psoriasis S Khatri, Y Amir, M Min, O Goldblum, K Solotkin, F Yang, T Ridenour, ... Journal of the European Academy of Dermatology and Venereology 30, 73-74, 2016 | 1 | 2016 |
| Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials J Soung, S Ständer, J Gutermuth, I Pau-Charles, Z Dawson, FE Yang, ... Journal of Dermatological Treatment 35 (1), 2329240, 2024 | | 2024 |
| 497-Lebrikizumab in combination with topical corticosteroids maintains improvements in itch and sleep at 68 weeks in patients with moderate-to-severe atopic dermatitis G Yosipovitch, PA Lio, D Rosmarin, M Casillas, FE Yang, C Hu, E Pierce, ... British Journal of Dermatology 190 (Supplement_2), ii6-ii7, 2024 | | 2024 |
| Analyse de la tolérance du baricitinib chez les patients adultes atteints de pelade sévère issus de 2 essais cliniques randomisés sur une période d’exposition médiane de 1, 6 … B King, J Ko, BM Piraccini, Y Shimomura, Y Dutronc, WS Wu, FE Yang, ... Annales de Dermatologie et de Vénéréologie-FMC 3 (8), A348-A349, 2023 | | 2023 |
| Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity LS Gold, K Eyerich, H Sofen, P Herranz, L Kircik, T Bewley, E Wolf, ... SKIN The Journal of Cutaneous Medicine 7 (6), s274-s274, 2023 | | 2023 |
| Patient-Level, Visit-by-Visit Data Highlight the Extent of Skin and Itch Improvement in Atopic Dermatitis With Lebrikizumab J Silverberg, L Kircik, M Gooderham, G Gallo, E Wolf, H Agell, FE Yang, ... SKIN The Journal of Cutaneous Medicine 7 (6), s275-s275, 2023 | | 2023 |
| 43018 Safety Analysis of Baricitinib in Adult Patients with Severe Alopecia Areata From 2 Randomized Clinical Trials over a Median of 1.6 years and up to 3.6 Years of Exposure B King, J Ko, BM Piraccini, Y Shimomura, Y Dutron, WS Wu, FE Yang, ... Journal of the American Academy of Dermatology 89 (3), AB220, 2023 | | 2023 |
